跳转至内容
Merck
CN

SML2802

ATR-101

≥98% (HPLC)

别名:

1[[1[4(Dimethylamino)phenyl]cyclopentyl]methyl]3[2,6di(propan2yl)phenyl]urea hydrochloride, ATR 101, ATR101, CI-984, N-[2,6-bis(1-Methylethyl)phenyl]-N-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea hydrochloride, Nevanimibe HCl, PD 132301 HCl, PD 132301-02, PD 132301-2, PD132301 HCl, PD132301-02, PD132301-2

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C27H39N3O·HCl
化学文摘社编号:
分子量:
458.08
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

[Cl-].N(C)(C)c1ccc(cc1)C3(CCCC3)CNC(=O)Nc2c(cccc2C(C)C)C(C)C.[H+]

InChI

1S/C27H39N3O.ClH/c1-19(2)23-10-9-11-24(20(3)4)25(23)29-26(31)28-18-27(16-7-8-17-27)21-12-14-22(15-13-21)30(5)6;/h9-15,19-20H,7-8,16-18H2,1-6H3,(H2,28,29,31);1H

InChI key

SDOOGTHIDFZUNM-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

Biochem/physiol Actions

ATR-101 (PD 132301-02; Nevanimibe HCl) is an orally active, potent and selective acyl-CoA:cholesterol acyltransferase 1 (ACAT1, SOAT1) inhibtior (IC50 = 52 nM; intestinal microsome from cholesterol-fed rabbits) that reduces plasma cholesterol in both acute (by 77%; 50 mg/kg po.) and chronic (by 80%; 10 mg/kg po.) cholesterol-fed rat models. In addition, ATR-101 is reported to exhibit therapeutic efficacy against adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH), and Cushing′s syndrome (CS).
Orally active, potent and selective acyl-CoA:cholesterol acyltransferase 1 (ACAT1, SOAT1) inhibtior.

存储类别

11 - Combustible Solids

wgk

WGK 3


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

J F Reindel et al.
Toxicologic pathology, 22(5), 510-518 (1994-09-01)
PD 132301-2, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, was administered orally to cynomolgus monkeys for 2 wk at doses of 25, 50, 100, and 200 mg/kg to assess potential subacute toxicity. Sporadic episodes of soft feces and diarrhea increased in
Yunhui Cheng et al.
Endocrine-related cancer, 23(4), 1-19 (2016-02-05)
Adrenocortical carcinoma (ACC) generally has poor prognosis. Existing treatments provide limited benefit for most patients with locally advanced or metastatic tumors. We investigated the mechanisms for the cytotoxicity, xenograft suppression, and adrenalytic activity of ATR-101 (PD132301-02), a prospective agent for
M A Dominick et al.
Fundamental and applied toxicology : official journal of the Society of Toxicology, 20(2), 217-224 (1993-02-01)
PD 132301-2 is a substituted urea hypolipidemic and antiatherosclerotic agent that is a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). To determine its subacute toxicity, PD 132301-2 was administered orally to beagle dogs at 0, 6, 12, 25, 50, 200, 400
M A Dominick et al.
Toxicologic pathology, 21(1), 54-62 (1993-01-01)
PD 132301-2, a novel inhibitor of acyl-CoA:cholesterol acyltransferase, is adrenotoxic to several laboratory animal species. Morphogenesis of a zona fasciculata-specific cytotoxicity was evaluated in male Hartley guinea pigs administered 100 mg/kg of PD 132301-2 for up to 7 days. Reversibility
L A Vernetti et al.
Toxicology and applied pharmacology, 118(1), 30-38 (1993-01-01)
A novel lipid regulator (PD132301-2) produces degeneration and necrosis of adrenal fasciculata in guinea pigs. Primary adrenocortical cell cultures from male Hartley guinea pigs were utilized to investigate potential mechanisms of this toxicity. Concentration-dependent loss of viability, measured by neutral

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持